James SL. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018. https://doi.org/10.1016/S0140-6736(18)32279-7.

Article  Google Scholar 

Immonen J, Jääskeläinen E, Korpela H, Miettunen J. Age at onset and the outcomes of schizophrenia: a systematic review and meta-analysis. Early Interv Psychiatry. 2017;11(6):453–60. https://doi.org/10.1111/eip.12412.

Article  Google Scholar 

Chong HY, Teoh SL, Wu DB, Kotirum S, Chiou CF, Chaiyakunapruk N. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357–73. https://doi.org/10.2147/NDT.S96649 (Published 2016 Feb 16).

Article  Google Scholar 

Ride J, Kasteridis P, Gutacker N, Aragon MJ, Jacobs R. Healthcare costs for people with serious mental illness in England: an analysis of costs across primary care, hospital care, and specialist mental healthcare. Appl Health Econ Health Policy. 2020;18(2):177–88. https://doi.org/10.1007/s40258-019-00530-2.

Article  Google Scholar 

Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149–60. https://doi.org/10.1002/wps.20516.

Article  Google Scholar 

Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P T. 2014;39(9):638–45.

Google Scholar 

Gaebel W, Stricker J, Hasan A, Falkai P, McIntyre JS, Kerst A. The revised DGPPN and APA schizophrenia guidelines: guideline quality and recommendations for long-term antipsychotic treatment. Schizophr Res. 2021;229:137–9. https://doi.org/10.1016/j.schres.2020.11.011 (Epub 2020 Nov 15 PMID: 33203610).

Article  Google Scholar 

Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010. https://doi.org/10.1016/j.psychres.2009.05.004.

Article  Google Scholar 

Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;8(13):50. https://doi.org/10.1186/1471-244X-13-50.

Article  Google Scholar 

Crismon L, Argo TR, Buckley PF, et al. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: a pathophysiologic approach. 9th ed. New York: McGraw-Hill; 2014. p. 1019–46.

Google Scholar 

Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014. https://doi.org/10.2147/PROM.S42735.

Article  Google Scholar 

Park SC, Choi MY, Choi J, Park E, Tchoe HJ, Suh JK, et al. Comparative efficacy and safety of long-acting injectable and oral second-generation antipsychotics for the treatment of schizophrenia: a systematic review and meta-analysis. Clin Psychopharmacol Neurosci. 2018. https://doi.org/10.9758/cpn.2018.16.4.361.

Article  Google Scholar 

Valsecchi P, Barlati S, Garozzo A, Deste G, Nibbio G, Turrina C, et al. Paliperidone palmitate in short- and long-term treatment of schizophrenia. Riv Psichiatr. 2019. https://doi.org/10.1708/3281.32542.

Article  Google Scholar 

Correll CU, Lauriello J. Using long-acting injectable antipsychotics to enhance the potential for recovery in schizophrenia. J Clin Psychiatry. 2020. https://doi.org/10.4088/JCP.MS19053AH5C.

Article  Google Scholar 

Biagi E, Capuzzi E, Colmegna F, Mascarini A, Brambilla G, Ornaghi A, et al. Long-acting injectable antipsychotics in schizophrenia: literature review and practical perspective, with a focus on aripiprazole once-monthly. Adv Ther. 2017. https://doi.org/10.1007/s12325-017-0507-x.

Article  Google Scholar 

Pappa S, Mason K, Howard E. Long-term effects of paliperidone palmitate on hospital stay and treatment continuation. Int Clin Psychopharmacol. 2019. https://doi.org/10.1097/YIC.0000000000000285.

Article  Google Scholar 

García-Carmona J, Barnett J, Campos-Navarro MP, Mason K, Valdivia-Muñoz F, Pappa S. Comparative effectiveness of long-acting injectable antipsychotics in a large naturalistic cohort across two European centres: findings from the long-acting injectable antipsychotics collaborative (LAICO) study. Neurosci Appl. 2022. https://doi.org/10.1016/j.nsa.2022.100111.

Article  Google Scholar 

Kishimoto J. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis. J Clin Psychiatry. 2013;74:957–65.

Article  Google Scholar 

Joint Formulary Committee. Paliperidone. In: British National Formulary (online). BMJ Group and pharmaceutical Press https://bnf.nice.org.uk/drug/paliperidone. Accessed 20 Feb 2022

Alphs L, Benson C, Cheshire-Kinney K, Lindenmayer JP, Mao L, Rodriguez SC, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015. https://doi.org/10.4088/JCP.14m09584.

Article  Google Scholar 

Pappa S, Mason K. Partial compliance with long-acting paliperidone palmitate and impact on hospitalization: a 6-year mirror-image study. Ther Adv Psychopharmacol. 2020. https://doi.org/10.1177/2045125320924789.

Article  Google Scholar 

Luther K, Fung GM, Khorassani F. Cost comparison of atypical antipsychotics: paliperidone ER and risperidone. Hosp Pharm. 2019;54(6):389–92. https://doi.org/10.1177/0018578718809269 (Epub 2018 Nov 4. PMID: 31762487; PMCID: PMC6852033).

Article  Google Scholar 

Bressington D, Stock J, Hulbert S, MacInnes D. A retrospective observational study of the effectiveness of paliperidone palmitate on acute inpatient hospitalization rates. Int Clin Psychopharmacol. 2015;30:230–6.

Article  Google Scholar 

Deslandes PN, Ward EH, Norris K, Sewell RD. Effectiveness of paliperidone long-acting injection in clinical practice. Ther Adv Psychopharmacol. 2018;8:139–45.

Article  Google Scholar 

Whale R, Pereira M, Cuthbert S, Fialho R. Effectiveness and predictors of continuation of paliperidone palmitate long-acting injection treatment: a 12-month naturalistic cohort study. J Clin Psychopharmacol. 2015;35:591–5.

Article  Google Scholar 

Taylor DM, Sparshatt A, O’Hagan M, Dzahini O. Effect of paliperidone palmitate on hospitalisation in a naturalistic cohort—a four-year mirror image study. Eur Psychiatry. 2016;37:43–8.

Article  Google Scholar 

Nikolić N, Page N, Akram A, Khan M. The impact of paliperidone palmitate long-acting injection on hospital admissions in a mental health setting. Int Clin Psychopharmacol. 2017;32:95–102.

Article  Google Scholar 

Taipale H, Mehtälä J, Tanskanen A, Tiihonen J. Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-a Nationwide study with 20-year follow-up. Schizophr Bull. 2018. https://doi.org/10.1093/schbul/sbx176.

Article  Google Scholar 

Mason K, Barnett J, Pappa S. Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate. Ther Adv Psychopharmacol. 2021. https://doi.org/10.1177/20451253211029490.

Article  Google Scholar 

Patel R, Chesney E, Taylor M, Taylor D, McGuire P. Is paliperidone palmitate more effective than other long-acting injectable antipsychotics? Psychol Med. 2018;48:1616–23.

Article  Google Scholar 

Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, Marder S, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A Randomized Clinical Trial. JAMA Psychiat. 2015. https://doi.org/10.1001/jamapsychiatry.2015.0270.

Article  Google Scholar 

Stahl SM. Long-acting injectable antipsychotics: shall the last be first? CNS Spectr. 2014;19:3–5.

Article  Google Scholar 

Samalin L, Garnier M, Auclair C, Llorca PM. Clinical decision-making in the treatment of schizophrenia: focus on long-acting injectable antipsychotics. Int J Mol Sci. 2016. https://doi.org/10.3390/ijms17111935.

Article  Google Scholar 

Pappa S, Barnett J, Gomme S, Iliopoulou A, Moore I, Whitaker M, et al. Shared and supported decision making in medication in a mental health setting: how far have we come? Community Ment Health J. 2021. https://doi.org/10.1007/s10597-021-00780-2.

Article  Google Scholar 

Kane JM, McEvoy JP, Correll CU, Llorca PM. Controversies surrounding the use of long-acting injectable antipsychotic medications for the treatment of patients with schizophrenia. CNS Drugs. 2021. https://doi.org/10.1007/s40263-021-00861-6.

Article  Google Scholar 

Taylor DM, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J Clin Psychiatry. 2009;70:196–200.

Article  Google Scholar 

Mace S, Dzahini O, O’Hagan M, Taylor D. Haloperidol decanoate long-acting injection (HDLAI): results of a 1-year mirror-image study. Ther Adv Psychopharmacol. 2018;8:241–9.

Article  Google Scholar 

Pantall SA, Pilsbury J, Gan L, Brownell L. A two-year mirror-image study of the effect of treatment with paliperidone and aripiprazole long-acting injections on need for inpatient care and home treatment intervention. BJPsych Open. 2021. https://doi.org/10.1192/bjo.2021.745.

Article  Google Scholar 

Subotnik KL, Casaus LR, Ventura J, et al. Longacting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiat. 2015;72(8):822–9.

Article  Google Scholar 

Schreiner A, Aadamsoo K, Altamura AC. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1–3):393–9.

Article  Google Scholar 

Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085–97.

Article  Google Scholar 

Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–23.

Article  Google Scholar 

Attard A, Olofinjana O, Cornelius V, Curtis V, Taylor D. Paliperidone palmitate long-acting injection–prospective year-long follow-up of use in clinical practice. Acta Psychiatr Scand. 2014;130:46–51.

Article  Google Scholar 

Olfson M, Ascher-Svanum H, Faries DE, Marcus SC. Predicting psychiatric hospital admission among adults with schizophrenia. Psychiatr Serv. 2011;62(10):1138–45.

Article  Google Scholar